Global Cardiovascular Disease Drugs Market to 2023 - Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape

  • ID: 4446680
  • Report
  • Region: Global
  • 228 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Bayer
  • Daiichi Sankyo
  • Johnson & Johnson
  • Merck & Co.
  • MORE

Summary

Cardiovascular disease (CVD) is a general term for a variety of different diseases and conditions affecting the heart or blood vessels. Cardiovascular events mostly occur as a result of the development of fatty deposits (atherosclerosis) in arteries obstructing blood flow to the brain, body or heart by causing a narrowing (stenosis) of blood vessels. Alternatively, blood clots can occur when part of an atherosclerotic plaque breaks off and either locally forms a thrombus, or travels down the blood stream and becomes blocked at a different point, forming an embolus.

CVD is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, diet and smoking, and non-modifiable factors such as age (as atherosclerosis develops naturally over time), genes, congenital dispositions, and gender. In addition, these primary risk factors also expose one to an increased risk of developing secondary risk factors, primarily hypertension and dyslipidemia.

CVD is the number one cause of death worldwide, with an estimated 17.7 Million deaths in 2015, with around 7.4 Million (over 41%) of these due specifically to CHD and about 6.7 Million (just over 39%) specifically due to stroke (WHO, 2017). The total economic impact of CVD, including both direct costs such as treatments and indirect costs such as productivity loss, is considerable and varies between countries. In the UK, total healthcare costs of CVD exceed $11 Billion annually, with annual economic costs of CVD exceeding $24 Billion annually (Townsend et al., 2012). In the US total costs associated with CVD were estimated to be as high as $656 Billion in 2015 and could rise to as high as $1.2 trillion by 2030.

Novartis recently launched Entresto (valsartan plus sacubitril), which is indicated specifically for the treatment of left ventricular heart failure with reduced EF. Most classes of CVD medications are very well established and as such the market is now heavily genericized.

Johnson & Johnson entered the market in 2008 with the approval of Xarelto, which Johnson & Johnson markets in the US via Janssen. Its share in revenue from this drug totaled $2.3 Billion in 2016 and this is expected to increase to $3.4 Billion by 2023. In January 2017, Johnson & Johnson acquired Actelion and with it Uptravi and Opsumit, which together will generate $5.4 Billion by 2023, enough to secure Johnson & Johnson’s place as market leader.

The report ""Global Cardiovascular Disease Drugs Market to 2023 - Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape"" provides an introduction to cardiovascular disease (CVD), including disease symptoms, diagnosis, etiology, pathophysiology, comorbidities and complications, epidemiology, prognosis and treatment.

Specifically, this report includes:

  • Overview of the CVD marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the CVD pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: hypertension, dyslipidemia, heart failure and thrombotic events.
  • Presents forecast projections to 2023 on a global level, with forecasts provided for the US and aggregate revenue forecasts for the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major molecular target classes in CVD are provided.
  • Assesses the company landscape in CVD, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals relating to CVD products.

Scope

  • With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?
  • The clinical trials process for CVD drugs is complex. What is the risk of a CVD drug failing to reach the market? What is the risk of a drug failing at a specific Phase?
  • The CVD market landscape is forecast to undergo a period of substantial change following key approvals, patent expiries and acquisitions. Which of the leading companies will have the highest market share by 2023? What strategies have these companies adopted to achieve market growth?
  • There has been a moderately high level of deal activity in recent years. How do deal frequency and value compare between target families and molecule types?

Reasons to buy

  • Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, comorbidities and complications, epidemiology, prognosis and treatment.
  • Recognize the leading therapeutics, as well as gaps in the market, with portfolios of key marketed products, including historical and forecast sales revenue patterns.
  • Identify trends and developments, in terms of molecule type and molecular target, within the overall CVD pipeline, as well as for key CVD indications: hypertension, heart failure, dyslipidemia and thrombotic events.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
  • Predict how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products and companies will make to this growth.
  • Understand how strategic consolidations have shaped the current pipeline and marketed products landscape.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Bayer
  • Daiichi Sankyo
  • Johnson & Johnson
  • Merck & Co.
  • MORE

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Diagnosis
2.3.1 Hypertension
2.3.2 Dyslipidemia
2.3.3 Imaging Tests
2.3.4 Stress Testing
2.4 Etiology, Pathophysiology, Comorbidities and Complications
2.4.1 Hypertension
2.4.2 Dyslipidemia
2.4.3 Heart Failure
2.4.4 Thrombosis
2.5 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
2.5.1 Hypertension
2.5.2 Dyslipidemia
2.5.3 Heart failure
2.5.4 Thrombotic events
2.6 Prognosis
2.7 Management and Treatment of Cardiovascular Disease
2.7.1 Pharmacological Intervention
2.7.2 Non-pharmacological Intervention
2.7.3 Unmet Need

3 Key Marketed Products
3.1 Overview
3.2 Lipitor (atorvastatin) - Pfizer
3.3 Crestor (rosuvastatin) - AstraZeneca
3.4 Zetia (ezetimibe) - Merck & Co.
3.5 Praluent (alirocumab) - Sanofi
3.6 Repatha (evolocumab) - Amgen
3.7 Plavix (clopidogrel) - Sanofi
3.8 Xarelto (rivaroxaban) - Bayer
3.9 Eliquis (apixaban) - Bristol Myers Squibb and Pfizer
3.10 Brilinta (ticagrelor) - AstraZeneca
3.11 Entresto (valsartan plus sacubitril) - Novartis
3.12 Benicar (olmesartan medoxomil) - Daiichi Sankyo
3.13 Bevyxxa (betrixaban) - Portola
3.14 Uptravi (selexipag) - Johnson & Johnson
3.15 Opsumit (macitentan) - Johnson & Johnson
3.16 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Assessment of Key Pipeline Products
4.5 Conclusion

5 Multi-Scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Coagulation Cascade
5.3.2 Renin angiotensin system
5.3.3 P2Y12 Receptors
5.3.4 HMG-CoA Reductase Inhibitors (statins)
5.3.5 PCSK9 Inhibitors
5.3.6 Beta 1 Adrenergic Receptors
5.3.7 Prostaglandin Receptors
5.3.8 Endothelin Receptors

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Value and Year
7.1.2 Deals by Indication
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type, Molecular Target and Value
7.1.5 List of Deals with Disclosed Deal Values
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Indication
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type, Molecular Target and Value
7.2.5 List of Deals with Disclosed Deal Values

8 Appendix
8.1 References
8.2 Tables of All Pipeline Products
8.3 Abbreviations
8.4 Disease List
8.4.1 Hypertension
8.4.2 Dyslipidemia
8.4.3 Heart failure
8.4.4 Thrombotic events
8.4.5 Other
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact
8.7 Disclaimer

List of Tables
Table 1: Cardiovascular Disease Drugs Market, US, Systolic and Diastolic Blood Pressure Level and Corresponding Category, 2017
Table 2: Cardiovascular Disease Drugs Market, Global, Total Cholesterol, LDL and HDL Levels and Corresponding Category, 2017
Table 3: Cardiovascular Disease Drugs Market, Global, Approved Indications for Lipitor, 2017
Table 4: Cardiovascular Disease Drugs Market, Global, Approved Indications for Crestor, 2017
Table 5: Cardiovascular Disease Drugs Market, Global, Approved Indications for Zetia, 2017
Table 6: Cardiovascular Disease Drugs Market, Global, Approved Indications for Praluent, 2017
Table 7: Cardiovascular Disease Drugs Market, Global, Approved Indications for Repatha, 2017
Table 8: Cardiovascular Disease Drugs Market, Global, Approved Indications for Plavix, 2017
Table 9: Cardiovascular Disease Drugs Market, Global, Approved Indications for Xarelto, 2017
Table 10: Cardiovascular Disease Drugs Market, Global, Approved Indications for Eliquis, 2017
Table 11: Cardiovascular Disease Drugs Market, Global, Approved Indications for Brilinta, 2017
Table 12: Cardiovascular Disease Drugs Market, Global, Approved Indications for Entresto, 2017
Table 13: Cardiovascular Disease Drugs Market, Global, Approved Indications for Benicar, 2017
Table 14: Cardiovascular Disease Drugs Market, Global, Approved Indications for Bevyxxa, 2017
Table 15: Cardiovascular Disease Drugs Market, Global, Approved Indications for Uptravi, 2017
Table 16: Cardiovascular Disease Drugs Market, Global, Approved Indications for Opsumit, 2017
Table 17: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for Inclisiran, 2017
Table 18: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for MEDI-6012, 2017
Table 19: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for Volanesorsen Sodium, 2017
Table 20: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for Vericiguat, 2017
Table 21: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for Bempedoic Acid, 2017
Table 22: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023 (part 1)
Table 23: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023 (part 2)
Table 24: Cardiovascular Disease Drugs Market, Global, Usage of Generics Across Key Indications, 2017
Table 25: Cardiovascular Disease Drugs Market, Global, Forecast Revenues by Company, 2016-2023
Table 26: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Discovery, 2017
Table 27: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Preclinical, 2017
Table 28: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2017
Table 29: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase I, 2017
Table 30: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase II, 2017
Table 31: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase III, 2017
Table 32: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Pre-registration, 2017
Table 33: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Unknown, 2017
Table 34: Abbreviations

List of Figures
Figure 1: Cardiovascular Disease Drugs Market, Global, Epidemiology Patterns for Hypertension, 2016-2023
Figure 2: Cardiovascular Disease Drugs Market, Global, Epidemiology Patterns for Dyslipidemia, 2016-2023
Figure 3: Cardiovascular Disease Drugs Market, Global, Epidemiology Patterns for Heart Failure, 2016-2023
Figure 4: Cardiovascular Disease Drugs Market, Global, Key Marketed Products and Approved Indications, 2017
Figure 5: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Lipitor ($bn), 2006-2023
Figure 6: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Crestor ($bn), 2006-2023
Figure 7: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Zetia ($bn), 2006-2023
Figure 8: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Praluent ($bn), 2015-2023
Figure 9: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Repatha ($bn), 2016-2023
Figure 10: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Plavix ($bn), 2006-2023
Figure 11: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Xarelto ($bn), 2011-2023
Figure 12: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Eliquis ($bn), 2012-2023
Figure 13: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Brilinta ($bn), 2011-2023
Figure 14: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Entresto ($bn), 2015-2023
Figure 15: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Benicar ($bn), 2006-2023
Figure 16: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Bevyxxa ($m), 2017-2023
Figure 17: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Uptravi ($bn), 2016-2023
Figure 18: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Opsumit ($bn), 2013-2023
Figure 19: Cardiovascular Disease Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
Figure 20: Cardiovascular Disease Drugs Market, Global, Pipeline by Stage of Development and Molecule Type, 2017
Figure 21: Cardiovascular Disease Drugs Market, Global, Pipeline for Key Cardiovascular Disease Indications by Stage of Development, 2017
Figure 22: Cardiovascular Disease Drugs Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecule Type, 2017
Figure 23: Cardiovascular Disease Drugs Market, Global, Pipeline by Molecular Target and Stage of Development, 2017
Figure 24: Cardiovascular Disease Drugs Market, Global, Pipeline by Molecular Target Breakdown, 2017
Figure 25: Cardiovascular Drugs Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecular Target, 2017
Figure 26: Cardiovascular Disease Drugs Market, Global, Clinical Program Attrition Rates by Stage of Development (%), 2006-2017
Figure 27: Cardiovascular Disease Drugs Market, Global, Clinical Trial Failure Rates (Phases I-III) and Overall Clinical Trial Attrition Rates by Indication (%), 2006-2017
Figure 28: Cardiovascular Disease Drugs Market, Global, Clinical Trial Failure Rates (Phases I-III) and Overall Clinical Trial Attrition Rates by Molecule Type (%), 2006-2017
Figure 29: Cardiovascular Disease Drugs Market, Global, Clinical Trial Failure Rates (Phases I-III) and Overall Clinical Trial Attrition Rates by Molecular Target (%), 2006-2017
Figure 30: Cardiovascular Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
Figure 31: Cardiovascular Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
Figure 32: Cardiovascular Disease Drugs, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
Figure 33: Cardiovascular Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
Figure 34: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017
Figure 35: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017
Figure 36: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
Figure 37: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017
Figure 38: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development (participants), 2006-2017
Figure 39: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development and Indication (participants), 2006-2017
Figure 40: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017
Figure 41: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
Figure 42: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Inclisiran ($bn), 2020-2023
Figure 43: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for MEDI-6012 ($m), 2020-2023
Figure 44: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Volanesorsen ($m), 2018-2023
Figure 45: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Vericiguat ($m), 2019-2023
Figure 46: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Bempedoic acid ($m), 2019-2023
Figure 47: Cardiovascular Disease Drugs Market, Global, Market Size ($bn), 2016-2023
Figure 48: Cardiovascular Disease Drugs Market, Global, Key Products Market Share, 2016-2023
Figure 49: Cardiovascular Drugs Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016-2023
Figure 50: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Targeting Elements of the Coagulation Cascade ($bn), 2016-2023
Figure 51: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Acting on RAS ($bn), 2016-2023
Figure 52: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for P2Y12 Inhibitors ($bn), 2016-2023
Figure 53: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for HMG-CoA Inhibitors ($bn), 2016-2023
Figure 54: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for PCSK9 Inhibitors ($bn), 2016-2023
Figure 55: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Beta Blockers ($bn), 2016-2023
Figure 56: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Acting on Prostaglandin Receptors ($bn), 2016-2023
Figure 57: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Acting on Endothelin Receptors ($bn), 2016-2023
Figure 58: Cardiovascular Disease Drugs Market, Global, Cluster by Growth and Market Share, 2016-2023
Figure 59: Cardiovascular Disease Drugs Market, Global, Company Analysis Matrix, 2017
Figure 60: Cardiovascular Disease Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023
Figure 61: Cardiovascular Disease Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
Figure 62: Cardiovascular Disease Drugs Market, Global, Sanofi Annual Revenue Forecast, 2016-2023
Figure 63: Cardiovascular Disease Drugs Market, Global, AstraZeneca Annual Revenue Forecast, 2016-2023
Figure 64: Cardiovascular Disease Drugs Market, Global, Novartis Annual Revenue Forecast, 2016-2023
Figure 65: Cardiovascular Disease Drugs Market, Global, Bayer Annual Revenue Forecast, 2016-2023
Figure 66: Cardiovascular Disease Drugs Market, Global, Pfizer Annual Revenue Forecast, 2016-2023
Figure 67: Cardiovascular Disease Drugs Market, Global, Johnson and Johnson, Annual Revenue Forecast, 2016-2023
Figure 68: Cardiovascular Disease Drugs Market, Global, Bristol-Myers Squibb, Annual Revenue Forecast, 2016-2023
Figure 69: Cardiovascular Disease Drugs Market, Global, Merck & Co, Annual Revenue Forecast, 2016-2023
Figure 70: Cardiovascular Disease Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Type, 2017
Figure 71: Cardiovascular Disease Drugs Market, Global, Pipeline, Overall, High-Activity and Late-Stage Developers by Level of Cardiovascular Specialization, 2017
Figure 72: Cardiovascular Disease Drugs Market, Global, Proportion of Total Company Revenue Attributed to Cardiovascular Disease, 2016-2023
Figure 73: Cardiovascular Disease Drugs, Global, Licensing Deals by Region, Value and Year, 200`6-2017
Figure 74: Cardiovascular Disease Drugs Market, Global, Licensing Deals by Indication, 2006-2017
Figure 75: Cardiovascular Disease Drugs, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2017
Figure 76: Cardiovascular Disease Drugs Market, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2017
Figure 77: Cardiovascular Disease Drugs Market, Global, Licensing Deals with Disclosed Deal Values, 2006-2017
Figure 78: Cardiovascular Disease Drugs, Global, Co-development Deals by Region, Value and Year, 2006-2017
Figure 79: Cardiovascular Drugs Market, Global, Co-development Deals by Indication, 2006-2017
Figure 80: Cardiovascular Disease Drugs Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 81: Cardiovascular Disease Drugs Market, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2017
Figure 82: Cardiovascular Disease Drugs Market, Global, Co-development Deals with Disclosed Deal Values, 2006-2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen
  • AstraZeneca
  • Bayer
  • Bristol Myers Squibb and Pfizer
  • Daiichi Sankyo
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Portola
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll